ClinicalTrials.gg
CompletedNCT00410072Updated Mar 15, 2013Results posted

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

A Phase 3 interventional study of Entecavir and Entecavir + Tenofovir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 68 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-03-15.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
2nd of 61
669 · median 109
Started
2007
with 6 others
Phase 3
13 of 64
none open now
Registered
8th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 2nd largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 3, and was the 8th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic virus (HBV) infection (hepatitis B e antigen [HbeAg]-positive or negative) disease
  • Nucleoside- and nucleotide-naive
  • Males or females ≥16 years of age (or minimum age of consent in a given country)
  • Compensated liver function
  • HBV DNA >1.72*10*5*IU/mL (approximately 10*6*copies/mL) for HbeAg-positive participants
  • HBV DNA >1.72*10*4*IU/mL (approximately 10*5*copies/mL) for Hbe-Ag-negative participants
  • level ≥* (ULN) and ≤10*ULN

Exclusion criteria

Exclusion Criteria:

  • Evidence of decompensated cirrhosis
  • Coinfection with , virus, or hepatitis D virus
  • Laboratory values out of protocol-specified range
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    TDF 0.5 mg

    TDF=tenofovir

    Drug: Entecavir

  • Experimental
    ETV 0.5 mg +TDF 300 mg

    ETV=entecavir; TDF=tenofovir

    Drug: Entecavir + Tenofovir

Interventions

  • Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks

    Also known as: Baraclude, BMS-200475

  • DrugEntecavir + Tenofovir

    Drug pages: Entecavir · Tenofovir

    Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96

    HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Week 96

Secondary outcomes

  1. Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status

    HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  2. Percentage of Participants Who Achieved HBV DNA Levels <LOQ by PCR at Weeks 48 and 96

    LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  3. Percentage of Participants Who Achieved HBV DNA Levels <LOD by PCR at Weeks 48 and 96

    LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  4. Mean Log 10 HBV DNA at Weeks 48 and 96

    HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load.

    Time frame: Baseline, Weeks 48 and 96

  5. Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96

    ALT normalization= ≤1\*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  6. Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96

    HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  7. Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96

    HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication.

    Time frame: At Weeks 48 and 96

  8. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96

    HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

    Time frame: At Weeks 48 and 96

  9. Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection.

    Time frame: At Weeks 48 and 96

  10. Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96

    Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.

    Time frame: At Weeks 48 and 96

  11. Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.

    Time frame: From enrollment through Week 100 + 24-week follow-up

  12. Number of Participants With HBV Resistance Through Week 48

    ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.

    Time frame: Week 48

  13. Number of Participants With HBV Resistance at Week 96

    ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.

    Time frame: Week 96

  14. Number of Participants With Virologic Breakthrough at Week 48

    ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed \>= 1 log10 increase in HBV DNA from the on-treatment nadir

    Time frame: Week 48

  15. Number of Participants With Virologic Breakthrough at Week 96

    ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed \>=1 log10 increase in HBV DNA from moving nadir

    Time frame: Week 96

07

Results

Posted Feb 3, 2012

Participant flow

Day 1 to Week 48
Participant flow — Day 1 to Week 48
MilestoneETV 0.5 mgETV 0.5 mg +TDF 300 mg
Started182197
Completed176185
Not completed612
Withdrew: Adverse event12
Withdrew: Lost to follow-up52
Withdrew: Other01
Withdrew: Poor compliance/noncompliance03
Withdrew: Pregnancy02
Withdrew: Withdrawal by subject02
After Week 48 to Week 96
Participant flow — After Week 48 to Week 96
MilestoneETV 0.5 mgETV 0.5 mg +TDF 300 mg
Started176185
Completed170174
Not completed611
Withdrew: Adverse event12
Withdrew: Death01
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up24
Withdrew: Other20
Withdrew: Poor compliance/noncompliance01
Withdrew: Pregnancy02
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96

HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 9676.483.2
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · Cochran-Mantel-Haenszel · p = 0.0882 · Mean difference (final values): 6.9 · 95% CI -1.0 to 14.9
SecondaryPercentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status

HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
HBeAg+ at Week 48 (n=126, n=138)61.174.6
HBeAg- at Week 48 (n=56, n=59)91.193.2
HBeAg+ at Week 96 (n=126, n=138)69.880.4
HBeAg- at Week 96 (n=56, n=59)91.189.8
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 13.5 · 95% CI 2.3 to 24.8
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 2.2 · 95% CI -7.7 to 12.0
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · Cochran-Mantel-Haenszel · p = 0.0460 · Mean difference (final values): 10.6 · 95% CI 0.2 to 21.0
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -1.2 · 95% CI -12.0 to 9.5
SecondaryPercentage of Participants Who Achieved HBV DNA Levels <LOQ by PCR at Weeks 48 and 96

LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HBV DNA Levels <LOQ by PCR at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Overall at Week 4867.674.6
Overall at Week 9674.781.7
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 7.1 · 95% CI -1.8 to 16.0
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 7.1 · 95% CI -1.1 to 15.2
SecondaryPercentage of Participants Who Achieved HBV DNA Levels <LOD by PCR at Weeks 48 and 96

LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HBV DNA Levels <LOD by PCR at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Overall at Week 4858.266.0
Overall at Week 9668.176.6
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 7.8 · 95% CI -1.5 to 17.1
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 8.6 · 95% CI -0.2 to 17.3
SecondaryMean Log 10 HBV DNA at Weeks 48 and 96

HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load.

Time frame:
Baseline, Weeks 48 and 96
Reported as:
Mean · log10 copies/mL
Mean Log 10 HBV DNA at Weeks 48 and 96
log10 copies/mLETV 0.5 mgETV 0.5 mg +TDF 300 mg
Baseline (n=182, 197)7.48 ± 0.1097.53 ± 0.100
Overall at Week 48 (n=176, 180)1.88 ± 0.0651.56 ± 0.026
Overall at Week 96 (n=165, 170)1.68 ± 0.0481.51 ± 0.038
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96

ALT normalization= ≤1\*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Overall at Week 4883.072.6
Overall at Week 9681.968.0
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC+F · Mean difference (final values): -10.4 · 95% CI -18.8 to -2.0
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -12.8 · 95% CI -21.5 to -4.1
SecondaryPercentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96

HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Week 4825.419.6
Week 963.9729.7
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -5.8 · 95% CI -15.9 to 4.2
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -9.2 · 95% CI -20.6 to 2.3
SecondaryPercentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96

HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Week 4822.218.1
Week 9632.521.7
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -4.1 · 95% CI -13.8 to 5.6
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -10.8 · 95% CI -21.5 to -0.1
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96

HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percent of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96
Percent of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Week 483.21.4
Week 964.05.1
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -1.7 · 95% CI -5.3 to 1.9
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 1.1 · 95% CI -3.9 to 6.1
SecondaryPercentage of Participants With HBsAg Seroconversion at Weeks 48 and 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Week 480.80.7
Week 961.62.9
Statistical analysis
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): -0.1 · 95% CI -2.2 to 2.0
  • ETV 0.5 mg vs ETV 0.5 mg +TDF 300 mg · NC=F · Mean difference (final values): 1.3 · 95% CI -2.3 to 4.9
SecondaryNumber of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96

Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.

Time frame:
At Weeks 48 and 96
Reported as:
Number · Percentage of participants
Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96
Percentage of participantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
< LOQ (29 IU/mL) at Week 4867.674.6
LOQ - <50 IU/mL at Week 482.75.6
50 - <172 IU/mL at Week 487.16.6
172 - <1720 IU/mL at Week 487.74.1
1720 - <17,200 IU/mL at Week 489.30.5
17,200 - <172,000 IU/mL at Week 481.60
≥172,000 IU/mL at Week 480.50
Missing at Week 483.38.6
< LOQ (29 IU/mL) at Week 9674.781.7
LOQ - <50 IU/mL at Week 961.61.5
50 - <172 IU/mL at Week 963.31.0
172 - <1720 IU/mL at Week 965.51.5
1720 - <17,200 IU/mL at Week 964.90
17,200 - <172,000 IU/mL at Week 960.50
≥172,000 IU/mL at Week 9600.5
Missing at Week 969.313.7
SecondaryNumber of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.

Time frame:
From enrollment through Week 100 + 24-week follow-up
Reported as:
Number · Participants
Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities
ParticipantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
Deaths03
SAEs1214
Adverse events132131
Discontinuations due to AEs25
Related AEs3949
SecondaryNumber of Participants With HBV Resistance Through Week 48

ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With HBV Resistance Through Week 48
ParticipantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
ETVr00
TDFr00
SecondaryNumber of Participants With HBV Resistance at Week 96

ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.

Time frame:
Week 96
Reported as:
Number · Participants
Number of Participants With HBV Resistance at Week 96
ParticipantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
ETVr00
TDFr00
SecondaryNumber of Participants With Virologic Breakthrough at Week 48

ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed \>= 1 log10 increase in HBV DNA from the on-treatment nadir

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With Virologic Breakthrough at Week 48
ParticipantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
ETVr00
TDFr00
SecondaryNumber of Participants With Virologic Breakthrough at Week 96

ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed \>=1 log10 increase in HBV DNA from moving nadir

Time frame:
Week 96
Reported as:
Number · Participants
Number of Participants With Virologic Breakthrough at Week 96
ParticipantsETV 0.5 mgETV 0.5 mg +TDF 300 mg
ETVr00
TDFr00

Adverse events

Collected over Week 0 to Week 100 (on study), Post-dosing follow-up - 24 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETV 0.5 mg—13/182 (7.1%)69/182 (37.9%)
ETV/TDF 0.5 mg +TDF 300 mg—14/197 (7.1%)73/197 (37.1%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventETV 0.5 mgETV/TDF 0.5 mg +TDF 300 mg
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1820/197
TRAUMATIC BRAIN INJURYInjury, poisoning and procedural complications0/1822/197
ACUTE PSYCHOSISPsychiatric disorders1/1820/197
OVARIAN CYSTReproductive system and breast disorders1/1820/197
CEREBRAL ISCHAEMIANervous system disorders1/1820/197
CEREBROVASCULAR ACCIDENTNervous system disorders1/1820/197
CHOLELITHIASISHepatobiliary disorders1/1820/197
DIABETIC COMPLICATIONMetabolism and nutrition disorders1/1820/197
BLOOD AMYLASE INCREASEDInvestigations1/1820/197
GASTRIC CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1820/197
Most frequent other events
Most frequent other events
EventETV 0.5 mgETV/TDF 0.5 mg +TDF 300 mg
HEADACHENervous system disorders19/18222/197
NAUSEAGastrointestinal disorders9/18220/197
NASOPHARYNGITISInfections and infestations11/18218/197
BACK PAINMusculoskeletal and connective tissue disorders13/1829/197
ABDOMINAL PAIN UPPERGastrointestinal disorders13/1828/197
DIARRHOEAGastrointestinal disorders11/18213/197
COUGHRespiratory, thoracic and mediastinal disorders7/18213/197
FATIGUEGeneral disorders11/18212/197

Baseline characteristics

Age, Customized
Age, Customized(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
16 - 20 years131932
21 - 64 years157169326
>=65 years12921
Sex: Female, Male
Sex: Female, Male(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Female6651117
Male116146262
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Asian84102186
Black/African American10414
Native Hawaiian/Other Pacific Islander112
White8387170
Other437
Country
Country(participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
United States354378
Turkey111122
Russian Federation242347
Italy121527
India5914
France8513
Canada293362
Argentina121527
Poland151328
Brazil538
Australia242448
South Africa235
Region
Region(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Africa235
Asia293362
Europe7067137
North America6476140
South America171835
Hepatitis B e antibody (HBeAb) at baseline
Hepatitis B e antibody (HBeAb) at baseline(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Positive6060120
Negative122137259
Hepatitis B e antigen (HBeAg) status at baseline
Hepatitis B e antigen (HBeAg) status at baseline(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Positive (> 172,000 IU/mL; approx 10^6 copies/mL)126138264
Negative (> 17,200 IU/mL; approx 10^5 copies/mL)5659115
Hepatitis B surface antigen (HBsAg) status at baseline
Hepatitis B surface antigen (HBsAg) status at baseline(Participants)ETV 0.5 mgETV 0.5 mg +TDF 300 mgTotal
Positive182196378
Negative011
08

Study locations

68 sites
  • Sergio E. Rojter
    Los Angeles, California 90017, United States
  • Tuan Nguyen, Md
    San Diego, California 92105, United States
  • San Jose Gastroenterology
    San Jose, California 95128, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06510, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30308, United States
  • Digestive Healthcare Of Georgia
    Atlanta, Georgia 30309, United States
  • Digestive Disease Associates, P.A.
    Baltimore, Maryland 21229, United States
  • Maryland Digestive Disease Research, Llc
    Laurel, Maryland 20707, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University Of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Sing Chan, Md
    Flushing, New York 11355, United States
  • North Shore University
    Manhasset, New York 11030, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • Concorde Medical Group
    New York, New York 10016, United States
  • Mount Sinai School Of Medicine
    New York, New York 10029, United States
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1121ABE, Argentina
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1181ACH, Argentina
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1282AEN, Argentina
  • Local Institution
    Rosario, Prov De Santa S2000PBJ, Argentina
  • Local Institution
    Westmead Nsw, New South Wales 2145, Australia
  • Local Institution
    Clayton Vic, Victoria 3168, Australia
  • Local Institution
    Fitzroy, Victoria 3065, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Prahan, Victoria 3004, Australia
  • Local Institution
    Belo Horizonte, Minas Gerais 30150, Brazil
  • Local Institution
    Porto Alegre Rs, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution
    Vancouver, British Columbia V5Z 1H2, Canada
  • Local Institution
    Winnipeg, Manitoba R3E 3P4, Canada
  • Local Institution
    Toronto, Ontario M3N 2V7, Canada
  • Local Institution
    Toronto, Ontario M5G 2N2, Canada
  • Local Institution
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution
    Grenoble Cedex 09, 38043, France
  • Local Institution
    Marseille Cedex 08, 13285, France
  • Local Institution
    Paris Cedex 12, 75571, France
  • Local Institution
    Paris Cedex 13, 75013, France
  • Local Institution
    Paris, 75014, France
  • Local Institution
    Strasbourg, 67090, France
  • Local Institution
    Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Lucknow, 226014, India
  • Local Institution
    Ludhiana, 141001, India
  • Local Institution
    Vellore, 632004, India
  • Local Institution
    Antella Firenze, 50012, Italy
  • Local Institution
    Brescia, 25123, Italy
  • Local Institution
    Pisa, 56124, Italy
  • Local Institution
    Roma, 00149, Italy
  • Local Institution
    Durango, 34229, Mexico
  • Local Institution
    Bialystok, 15-540, Poland
  • Local Institution
    Chorzow, 41-500, Poland
  • Local Institution
    Krakow, 31-531, Poland
  • Local Institution
    Lublin, 20-081, Poland
  • Local Institution
    Warszawa, 01-201, Poland
  • Local Institution
    Moscow, 105275, Russian Federation
  • Local Institution
    Moscow, 115446, Russian Federation
  • Local Institution
    Moscow, 117593, Russian Federation
  • Local Institution
    Smolensk, 214018, Russian Federation
  • Local Institution
    St. Petersburg, 190103, Russian Federation
  • Local Institution
    St. Petersburg, 191163, Russian Federation
  • Local Institution
    St. Petersburg, 191167, Russian Federation
  • Local Institution
    St. Petersburg, 194044, Russian Federation
  • Local Institution
    Pretoria, Gauteng 0001, South Africa
  • Local Institution
    Bellville, Western Cape 7530, South Africa
  • Local Institution
    N1 City Goodwood, Western Cape 7463, South Africa
  • Local Institution
    Bornova Izmir, 35100, Turkey
  • Local Institution
    Cebeci Ankara, 06620, Turkey
  • Local Institution
    Sihhiye Ankara, 06100, Turkey
  • Local Institution
    Trabzon, 61080, Turkey
09

References and documents

Publications

  • Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012 Sep;143(3):619-628.e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27. PubMed 22643350 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 12, 2006
Start
Apr 2007
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Feb 3, 2012
Last update
Mar 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00410072
Responsible party
Sponsor
First posted
Dec 12, 2006
Start date
Apr 2007
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Feb 3, 2012
Last update
Mar 15, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Tenofovir

Start the discussion